Custom-Made vaccine takes on liver cancer after surgery
NCT ID NCT04912765
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests a personalized dendritic cell vaccine combined with the immunotherapy drug nivolumab in 60 people who had surgery for liver cancer or colorectal cancer that spread to the liver. The vaccine is made from each patient's unique tumor mutations and aims to train the immune system to recognize and destroy any remaining cancer cells. The goal is to see if this combination can improve relapse-free survival and trigger a strong immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized dendritic cell vaccine and nivolumab (Opdivo)
What this could lead to
If successful, this combination could help prevent liver cancer or colorectal liver metastases from coming back after surgery.
What could go wrong
This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. The vaccine is personalized, making it complex and costly to produce.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center Singapore
RECRUITINGSingapore, 169690, Singapore